Common Lyme Disease Tests Miss Majority of Early Cases, New Research Finds
Early detection is critical for treating Lyme disease effectively, yet the very tools doctors rely on may be failing a significant number of patients. New research reveals that commonly used FDA-cleared diagnostic testing methods miss between 64% and 78% of early Lyme disease cases, including patients who present with the hallmark “bullseye” rash.
- FDA-cleared diagnostic tests missed 64-78% of early Lyme disease cases in a recent study.
- Only 39% of participants with early infection tested positive using any of the four tested algorithms.
- Current tests rely on antibody detection, which often fails in the first one to two weeks of infection.
- Experts are calling for diagnostics that directly detect the bacteria rather than the immune response.
The Gap in Early Lyme Detection
A large-scale, head-to-head study published in the Journal of Clinical Microbiology has highlighted a dangerous limitation in how we diagnose Lyme disease. The research, based on data from the Bay Area Lyme Foundation’s Lyme Disease Biobank, evaluated 107 early Lyme disease cases to determine the accuracy of current testing standards.
The study compared two standard two-tiered testing (STTT) and two modified two-tiered testing (MTTT) diagnostic algorithms. Despite these being the primary methods used by providers and major national laboratories, they proved highly insensitive. In total, only 39% of the evaluated early-stage patients tested positive by any of the four algorithms.
Why Current Tests Fail
The primary reason for these missed diagnoses lies in the biological mechanism of the tests. Current FDA-cleared algorithms rely on antibody detection. When a person is infected with the bacteria that cause Lyme disease, the body eventually produces antibodies to fight the infection. However, there is a critical window—typically the first one to two weeks—where the bacteria are present, but the body hasn’t produced enough antibodies to be detectable by a test.
This lag in antibody production means that patients can be actively infected and showing symptoms, yet still receive a negative test result. This is particularly concerning for patients presenting with erythema migrans (EM), the characteristic Lyme rash, who are still frequently missed by these diagnostic tools.
“This study demonstrates that common two-tiered Lyme tests, utilized for decades, often fail to detect early Lyme disease and are leaving patients behind, highlighting a critical need for improved medical education on the limitations of current diagnostics,” said Liz Horn, PhD, MBI, Principal Investigator of Lyme Disease Biobank and lead author of the study.
The Path Toward Better Diagnostics
The findings underscore an urgent need to move beyond antibody-based testing. Because the current system waits for the immune system to respond, it creates a window of vulnerability for the patient. According to Dr. Horn, the medical community needs diagnostics that can directly detect the bacteria that cause Lyme disease, rather than the antibodies the body produces in response to them.
Until such technology becomes the standard of care, improved medical education is essential. Clinicians must understand that a negative test result in the early stages of suspected infection does not necessarily rule out Lyme disease.
Frequently Asked Questions
What is a “two-tiered” test?
Two-tiered testing is the standard diagnostic approach for Lyme disease. It typically involves an initial screening test (like an ELISA), and if that is positive, a second, more specific confirmatory test (like a Western blot) is performed.
What should I do if I have a rash but a negative Lyme test?
Because antibody levels take time to rise, a negative test in the first few weeks of infection is common. It’s important to discuss your symptoms, including any history of tick bites or the presence of an erythema migrans rash, with your healthcare provider, as clinical diagnosis often takes precedence over laboratory results in early stages.
Does this mean all Lyme tests are useless?
No. These tests are more effective in later stages of the disease when the immune system has had ample time to produce detectable antibodies. The issue highlighted by the research is specifically regarding early detection.
Looking Ahead
The publication of this data in the Journal of Clinical Microbiology serves as a wake-up call for the diagnostic industry and the medical community. By shifting the focus toward direct bacterial detection and increasing provider awareness of testing limitations, the healthcare system can reduce the number of patients who go untreated during the most critical window for recovery.